Evogene Stock (NASDAQ:EVGN)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$2.84

52W Range

$2.29 - $10.40

50D Avg

$3.54

200D Avg

$6.53

Market Cap

$14.17M

Avg Vol (3M)

$27.86K

Beta

1.02

Div Yield

-

EVGN Company Profile


Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IL

Employees

142

IPO Date

Oct 15, 2010

Website

EVGN Performance


EVGN Financial Summary


Dec 23Dec 22Dec 21
Revenue$5.64M$1.68M$930.00K
Operating Income$-26.51M$-26.94M$-30.95M
Net Income$-23.88M$-29.84M$-30.45M
EBITDA$-23.90M$-23.84M$-26.78M
Basic EPS$-0.52$-0.72$-0.75
Diluted EPS$-0.52$-0.72$-0.75

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 22, 24 | 5:42 PM
Q1 24May 23, 24 | 12:00 AM
Q4 23Mar 07, 24 | 1:35 PM

Peer Comparison


TickerCompany
ZVSAZyVersa Therapeutics, Inc.
CKPTCheckpoint Therapeutics, Inc.
BDRXBiodexa Pharmaceuticals Plc
GMDAGamida Cell Ltd.
ONCROncorus, Inc.
LEXXLexaria Bioscience Corp.
SURFSurface Oncology, Inc.
FATEFate Therapeutics, Inc.
ALDXAldeyra Therapeutics, Inc.
RCUSArcus Biosciences, Inc.
PLURPluri Inc.
CLGNCollPlant Biotechnologies Ltd.
CRVSCorvus Pharmaceuticals, Inc.
CGENCompugen Ltd.
ICCCImmuCell Corporation